WO1995025742A1 - Antigenes de pasteurellaceae et vaccins associes - Google Patents

Antigenes de pasteurellaceae et vaccins associes Download PDF

Info

Publication number
WO1995025742A1
WO1995025742A1 PCT/IB1995/000185 IB9500185W WO9525742A1 WO 1995025742 A1 WO1995025742 A1 WO 1995025742A1 IB 9500185 W IB9500185 W IB 9500185W WO 9525742 A1 WO9525742 A1 WO 9525742A1
Authority
WO
WIPO (PCT)
Prior art keywords
antigens
pasteurella multocida
bacteria
approximately
kilodaltons
Prior art date
Application number
PCT/IB1995/000185
Other languages
English (en)
Inventor
Robert Gerard Ankenbauer
Krishnaswamy Iyengar Dayalu
Wanda Kay Isaacson
Thomas James Kaufman
Wumin Li
Nancy Ellen Pfeiffer
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to JP7524520A priority Critical patent/JPH09505085A/ja
Priority to EP95910704A priority patent/EP0751956A1/fr
Priority to AU18600/95A priority patent/AU1860095A/en
Publication of WO1995025742A1 publication Critical patent/WO1995025742A1/fr
Priority to MXPA/A/1996/004262A priority patent/MXPA96004262A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • Animal vaccines designed to protect against pneumonias caused by Pasteurellaceae are generally produced from inactivated whole bacteria or extracts of bacterial cultures.
  • the protective potential of potassium thiocyanate extracts of culture-grown Pasteurella multocida have been investigated in mice, chickens, cattle and rabbits. These extracts contained protein, hyaluronic acid, lipopolysaccharide, DNA and RNA, making interpretation of the protective component difficult. Although some cross- protection has been observed, protection was mainly against homologous challenge.
  • Antibodies specific for polypeptides of approximately 153 kD, 179 kD, 192 kD and 204 kD recovered from in vivo- grown bacteria that were detergent insoluble have also been demonstrated to provide passive cross-protection against heterologous challenge in poultry (Wang CL et al. Abstract #32, p. 8, Conference of Research Workers in Animal Diseases, November 9-10, 1992, Chicago, IL) .
  • This antiserum was adsorbed against culture grown bacteria to remove antibodies that reacted with antigens in the culture grown preparation.
  • Induction of the pheST operon (which encodes two subunits of phenylalanyl-tRNA synthetase) is believed to be a response to the depletion of a charged tRNA, indicating starvation for the aromatic amino acid phenylalanine.
  • Pasteurella multocida isolates of turkey origin cultured in media containing iron chelators express novel outer membrane proteins that are not synthesized in standard, enriched culture media.
  • novel proteins are the cross- protective factors observed in in vivo-grown bacteria.
  • This relationship between the iron regulated outer membrane proteins and the outer membrane proteins of in vivo grown bacteria was investigated by comparison of their protein profiles by SDS-PAGE.
  • Antigens from the Pasteurella multocida and Actinobacillus pleuropneumoniae isolated directly from the pleural cavities of infected swine or from a minimal medium formulation have now been identified. These antigens are proteins which are up-regulated during infection in a host animal and are not observed during culture in standard, enriched media. It has now been found that these antigens are up-regulated in minimal medium formulations. However, these antigens are absent or only weakly expressed during in vitro cultivation in standard, enriched media. An immune response to these newly identified antigens invokes protection against heterologous challenge. Therefore, these antigens are useful in the production of an effective vaccine providing cross-protection between multiple isolates of the same species.
  • An object of the present invention is to provide antigens of the Pasteurella , Actinobacillus and Haemophilus species of bacteria capable of being up-regulated during infection in a host animal and in minimal medium formulations which provide protection against infections caused by these species.
  • Another object of the present invention is to provide vaccines comprising antigens of the Pasteurella , Actinobacillus and Haemophilus species of bacteria capable of being up-regulated during infection in a host animal and in minimal medium formulations which provide protection against infections caused by these species.
  • Yet another object of the present invention is to provide a method of immunizing healthy animals against infections caused by Pasteurella , Actinobacillus and
  • Haemophilus species of bacteria which comprises administering to a healthy animal an effective amount of a -6-
  • vaccine comprising antigens of the Pasteurella , Actinobacillus and Haemophilus species of bacteria capable of being up-regulated during infection in a host animal and in minimal medium formulations which provide protection against infections caused by these species.
  • Figure l is a graph depicting a passive immunity study in mice. All mice received 0.5 ml, i.p. , of an immune serum followed four hours later by 100 to 200 CFU of virulent Pasteurella multocida 16926.
  • immune serum was collected from a pig following a primary infection with P. multocida isolate 8261.
  • Group A (-) serum is a 1:10 dilution of this immune serum;
  • Group B ( )serum is a 1:10 dilution of this immune serum adsorbed with detergent solubilized, standard, enriched media grown isolate 8261; and
  • Group C is preimmune serum diluted 1:10.
  • FIG. IB immune serum was collected from a pig infected with isolate 8261 followed by a secondary exposure to P. multocida isolate 16926.
  • Group D (— —) serum is a 1:10 dilution of this immune serum
  • Group E (— ⁇ • —) serum is a 1:10 dilution of this immune serum adsorbed with detergent solubilized, standard, enriched media grown isolate 8261
  • Figure 2 is a graph depicting a second passive immunity study in mice. All mice received 0.5 ml, i.p. of an immune serum followed four hours later by 100 to 200 CFU of virulent P . multocida 16929. Immune serum was collected from a pig 7 days following a secondary exposure to P. multocida isolate 16926.
  • Group 1 (— —) is preimmune serum diluted 1:10
  • Group 2 (—) is immune serum diluted 1:10;
  • Group 3 is immune serum, treated with detergent and purified, diluted 1:10;
  • Group 4 is immune serum, adsorbed with detergent-solubilized bacteria and purified, diluted 1:10; and
  • Group 5 is lung washing fluids collected 18 hours following secondary exposure to isolate 16926.
  • the Pasteurellaceae family of bacteria contains species of the genera Pasteurella , Actinobacillus , and Haemophilus . Recent work on the phylogeny of the Pasteurellaceae family confirmed the grouping of these three genera into this family (Dewhirst et al. (1992) J . Bacteriol . 174:2002-2013).
  • the various species within the Pasteurellaceae family fall into four large clusters, each cluster containing species of three different genera. Examples of species within this family include, but are not limited to, the animal pathogens P . multocida , A. pleuropneumonia , P. haemolytica , H. somnus , and A. suis .
  • Pasteurellaceae infections in animals result in symptoms similar to those resulting from virulent septic pneumonia. Death is generally due to endotoxic shock and respiratory failure. High mortality rates can occur with the acute form of these infections, however, subacute and chronic forms which result in pleuritis are more common. Treatment of field infections is difficult and often unsuccessful due to widespread antibiotic resistance. Therefore, it is preferred to prevent the infection in animals through use of a vaccine. There has been difficulty, however, in achieving a vaccine which will provide protection against different isolates of a species of bacteria within the Pasteurellaceae family.
  • the present invention provides antigens from the Pasteurella , Actinobacillus and Haemophilus species of bacteria that are up-regulated during infection in a host animal or in minimal medium formulations but which are absent or only weakly expressed during in vitro cultivation of the bacteria in a standard, enriched media, said antigens being capable of providing protection against an infection by these species of bacteria.
  • These antigens provide the basis for effective vaccines designed to cross-protect animals from infection by multiple isolates of one of the Pasteurella , Actinobacillus or Haemophilus species of bacteria.
  • host animals for these bacteria include, but not limited to, swine, bovine, ovine, avian and equine species.
  • minimal medium formulations it is meant a culture media specifically designed to provide a sufficient concentration of nutrients to bacteria to allow for synthesis of antigens up-regulated in vivo in a host while removing all undefined components.
  • standard, enriched laboratory media are designed to allow optimal growth of bacteria and thus include an excessive levels of nutrients when compared to the minimal growth requirements for each species.
  • HP Heamophilus Pleuropneumoniae
  • Undefined components in these media such as yeast extract, tryptone, peptone or brain heart infusion all contain high levels of complexed nitrogen, amino acids, vitamins, iron and other minerals which provide an excellent nitrogen source " and general nutritional supplement so that little metabolic demand is placed on the bacteria.
  • culture media used in the present invention were designed to supply the bacteria with the minimum level of essential nutrients necessary to support growth, thus mimicking the environment encountered when bacteria invade the host organism.
  • Components of the minimal media used in the present invention comprise basal salts (elemental requirements) , carbon sources, special nutritional requirements of the Pasteurellaceae , and nonessential optimizing supplements.
  • basal salts include, but are not limited to, potassium phosphate, potassium sulfate, magnesium chloride, ammonium chloride, calcium chloride and sodium chloride.
  • elemental requirements include, but are not limited to, potassium, sulfur, phosphorus, sodium, chloride, and calcium.
  • carbon sources include, but are not limited to, glycerol and lactic acid. Glucose, galactose, fructose, mannose, sucrose, mannitol, and sorbitol can also be utilized by the Pasteurellaceae . However, because of the fermentative type of metabolism of these organisms, acid can be produced during catabolism of sugars resulting in a lower yield of bacterial cells in the culture.
  • non- fermentable carbohydrates glycerol and lactic acid which do not lead to acid accumulation in cultures, is preferred.
  • members of the Pasteurellaceae are not prototrophic in that they are unable to grow in a mineral salts medium with a single carbon source, special nutritional additives are required.
  • these species require organic nitrogen sources and may require several amino acids, B vitamins, 0-nicotinamide, adenine nucleotides, or protoporphyrin and its conjugates.
  • the minimal medium may comprise arginine, aspartic acid, cystine, gluta ic acid, glycine, leucine, lysine, methionine, serine, tyrosine, inosine, uracil, hypoxanthine, thiamine, pantothenate, and nicotihamide.
  • protoporphyrin or its conjugates can also be added as needed. The addition of several components were also found to enhance the cell yield of P. multocida and A. pleuropneumoniae .
  • non-essential optimizing supplements include a buffer such as HEPES to increase buffering capacity, a nitrogen source such as glutamic acid and Casamino acid (a semi-defined acid hydrolysate of casein, Difco Laboratories Ltd, West Molesey, Surrey KT8 OSE U.K.), and an organic sulfur source such as L-cysteine.
  • these minimal media formulations contains no iron, zinc, copper, manganese or cobalt salts or complex biological materials containing these minerals.
  • the sole source for these minerals is the trace amounts which may be present as trace contaminants in the various other defined components or water.
  • the laboratory analyses of trace minerals in these minimal media formulations are provided in the following table.
  • Pasteurellaceae species such as Pasteurella multocida of
  • Actinobacillus pleuropneumoniae bacteria is administered to a host animal, preferably a pig, by injection into the pleural cavity.
  • the host animal is euthanized approximately 12 to 18 hours later and the pleural fluids are collected. Large cellular debris is removed from the fluids, and in vivo- grown bacteria are recovered by centrifugation. The resulting bacterial pellet is washed several times in buffer and centrifuged. The bacterial pellets are then resuspended in buffer and stored at -70°C.
  • Pasteurellaceae bacteria such as P. multocida or A. pleuropneumoniae are grown in a minimal medium formulation. Cultured bacteria were centrifuged to concentrate the bacteria and remove media components. Bacterial pellets were resuspended in PBS to an optical density of approximately 3.0 and frozen at -70°C until analyzed. Proteins expressed by the in vivo-grown bacteria or bacteria grown in a minimal medium formulation are separated by gel electrophoresis. Those proteins which are strongly expressed can then be identified by transferring part of the gel to nitrocellulose for Western blot analysis using immune serum that has been adsorbed against in vitro-grown bacteria in a standard, enriched media or using antibody recovered from the local site of infection.
  • strongly expressed refers to proteins up-regulated or expressed during infection in a host animal or in bacteria grown in a minimal medium formulation which are absent or only weakly expressed during conventional in vitro cultivation in standard laboratory medium.
  • weakly expressed refers to expression in amounts so minor that the antigen is incapable of providing protection against a Pasteurellaceae infection.
  • Conventional in vitro cultivation refers to bacteria inoculated into a standard, enriched medium such as complete Heamophilus Pleuropneumoniae (HP) medium containing supplements. The inoculate is incubated at 37°C for several hours, preferably in a shaking incubator.
  • the bacteria are centrifuged at 10,000 x g to remove culture medium and resuspended in sterile PBS (10 mM phosphate, 0.87% NaCl, pH 7.2) prior to use.
  • sterile PBS 10 mM phosphate, 0.87% NaCl, pH 7.2
  • At least eleven antigens were identified from the Western blot analysis of in vivo grown bacteria that are absent from Pasteurella multocida grown in vitro using in a standard, enriched media.
  • Western blot analysis of bacteria grown in vitro in a minimal medium formulation demonstrated that the antigenic profile of bacterial proteins produced in this minimal medium formulation was identical to the antigenic profile produced in a host animal infected by the bacteria.
  • the corresponding protein bands had molecular weights of approximately 115 kD, 109 kD, 96 kD, 89 kD, 79 kD, 62 kD, 56 kD, 53 kD, 45 kD, 34 kD and 29 kD.
  • the corresponding protein bands for each antigen are then excised from the gel, re-isolated by gel-electrophoresis and transferred onto sequence membranes for N'-terminal amino acid sequencing.
  • the N'-terminal amino acid sequence of a 34 kD antigen is as follows:
  • N'-terminal amino acid sequence of 29 kD antigen is as follows:
  • Lys Phe Lys Val Gin lie Ala XXX XXX XXX Gin Asp He Asn Gin Tyr Tyr Ala Gly Asp Ala Ala Phe Val (SEQ ID NO: 3)
  • SEQ ID NO: 3 The ability of these antigens to invoke a protective immune response against Pasteurellaceae was verified in passive transfer experiments.
  • Antibodies to the bacteria were isolated from infected pigs. Those antibodies that were rendered specific for the antigens of the present invention by adsorption were administered to mice. These mice were then challenged with a virulent heterologous isolate of Pasteurella multocida . Control mice not receiving the antibodies developed infections while those receiving the antibodies did not.
  • antibodies developed as an immune response against these antigens provided cross protection against heterologous isolates of Pasteurella multocida .
  • vaccines were prepared from P. multocida cultured in standard, enriched media containing yeast extract and from bacteria cultured in a minimal medium formulation.
  • the vaccine prepared from bacteria cultured in standard, enriched media was unable to protect mice from either homologous or heterologous challenge of P. multocida .
  • mice immunized with the vaccine prepared from bacteria cultured in a minimal medium formulation had much better survival rates.
  • Pasteurella multocida antigens which are capable of being up-regulated during infection in a host animal and in a minimal media formulation which provide protection against a Pasteurella infection.
  • a Pasteurella multocida antigen has a molecular weight, as determined by gel electrophoresis, of approximately 115 kD.
  • a Pasteurella multocida antigen has a molecular weight, as determined by gel electrophoresis, of approximately 109 kilodaltons.
  • a Pasteurella multocida antigen has a molecular weight, as determined by gel electrophoresis, of approximately 96 kilodaltons.
  • a Pasteurella multocida antigen has a molecular weight, as determined by gel electrophoresis, of approximately 89 kilodaltons. In yet another embodiment, a Pasteurella multocida antigen has a molecular weight, as determined by gel electrophoresis, of approximately 79 kilodaltons. In yet another embodiment, a Pasteurella multocida antigen has a molecular weight, as determined by gel electrophoresis, of approximately 62 kilodaltons. In yet another embodiment, a Pasteurella multocida antigen has a molecular weight, as determined by gel electrophoresis, of approximately 56 kilodaltons.
  • a Pasteurella multocida antigen has a molecular weight, as determined by gel electrophoresis, of approximately 53 kilodaltons. In yet another embodiment, a Pasteurella multocida antigen has a molecular weight, as determined by gel electrophoresis, of approximately 45 kilodaltons. In a preferred embodiment, a Pasteurella multocida antigen has a molecular weight, as determined by gel electrophoresis, of approximately 29 kilodaltons and an N'-terminal amino acid sequence comprising SEQ ID NO: 2.
  • a Pasteurella multocida antigen has a molecular weight, as determined by gel electrophoresis, of approximately 29 kilodaltons and an N'- terminal amino acid sequence comprising SEQ ID NO: 3. It is also preferred that a Pasteurella multocida antigen has a molecular weight, as determined by gel electrophoresis, of approximately 34 kilodaltons and an N'-terminal amino acid sequence comprising SEQ ID NO: 1.
  • Antigens up-regulated during infection in a host animal and in a minimal media formulation but not in bacteria grown in vitro in a standard, enriched media were also identified for isolates of Actinobacillus pleuropneumoniae .
  • A. pleuropneumoniae is member of the Pasteurellaceae family which exists in the most distinct phylogenetic cluster from that of P . multocida .
  • the most prominent antigenic difference between the in vivo or minimal media bacteria and the bacteria cultured in a standard, enriched media was the presence of additional bands of approximately 60 kD to 65 kD in the in vivo and minimal media preparations.
  • the antigens of Pasteurellaceae can be produced recombinantly using techniques well-known to those skilled in the art or induced in culture via genetic manipulation.
  • Antigens of the present invention may be incorporated into a vaccine and administered to a healthy animal in an effective amount to protect against infection by bacteria of the Pasteurellaceae family. Upon administration, the antigens in the vaccine will invoke an immune response resulting in the healthy animal forming antibodies against the bacteria. "Effective amount” refers to that amount of vaccine which invokes in an animal an immune response sufficient to result in production of antibodies to the antigens. The animal will then be protected from any subsequent exposure to an isolate of Pasteurellaceae .
  • Pasteurella multocida comprises at least one antigen having a molecular weight of 34 kD and an N'-terminal amino acid sequence comprising SEQ ID NO: 1 or a molecular weight of 29 kD and an N'-terminal amino acid sequence comprising SEQ ID NO: 2 or SEQ ID NO: 3.
  • the antigen can be dissolved or suspended in any pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carriers include, but are not limited to, normal isotonic saline, standard 5% dextrose in water or water, preferably adjuvanted.
  • adjuvants include, but are not limited to, Quil A, Alhydrogel, and Quil A and 5% Alhydrogel in tissue culture media.
  • the vaccine can be administered subcutaneously, intramuscularly, intraperitoneally, intravitreally, orally. intranasally or by suppository at doses ranging from approximately 1 to 100 ⁇ g/dose.
  • the antigens of the present invention produced in vivo or in bacteria grown in vitro in a minimal media formulation, recombinantly or via genetic manipulation or under specialized culture conditions can be added to whole culture grown bacteria to produce an effective vaccine. Addition of these antigens to the culture grown bacteria increase the efficacy of the resulting vaccine.
  • Example 1 Bacterial isolates and growth conditions Pasteurella multocida isolates 8261 and 16926 were field isolates received from the Iowa State Veterinary Diagnostic laboratory. Both isolates were serotype 3A.
  • bacteria were inoculated into Heamophilus Pleuropneumoniae (HP) medium (Gibco, Grand Island, NY) containing supplements, and incubated for 6 hours at 37°C in a shaking incubator. The bacteria were centrifuged at 10,000 x g to remove culture medium and resuspended in sterile PBS (10 mM phosphate, 0.87% NaCl, pH 7.2).
  • HP Heamophilus Pleuropneumoniae
  • Example 2 Convalescent sera and antibody from immune, challenged pigs
  • the pigs were allowed to convalesce for a period of between 10 days to one month and then treated with antibiotics to clear any residual infection. Following an additional period of one to two months, the pigs were exposed to a heterologous isolate of PmA (8261 or 16926) by the transthoracic route (1.5 - 2.5 x 10" CFU/ml). The pigs were euthanized at day 0, 1, 2, 3, 4, or 7. Serum samples were collected from the pigs at the time of primary infection, one month following primary infection, at the time of second infection, and at the time of euthanasia.
  • Lung washings were recovered from the pigs at the time of euthanasia to obtain antibody from the local site of infection.
  • the lungs and trachea were rinsed with approximately 100 ml of sterile PBS.
  • the lungs were massaged, and then fluids containing the antibody were poured into sterile tubes.
  • the fluids were centrifuged at 250 x g for 20 minutes at 4°C to remove large cellular debris and red blood cells.
  • Example 3 Adsorption of antibody preparations with detergent-solubilized or whole Pasteurella multocida
  • Antibodies that recognize in vitro grown bacterial antigens were removed by adsorption against either whole bacteria or detergent-solubilized antigen.
  • Fresh culture grown bacteria (isolate 8261 or 16926) were obtained for the whole bacteria adsorptions.
  • Approximately 10 ml of bacteria (3 x 10 9 CFU/ml) were pelleted by centrifugation at 11,000 x g for 40 minutes at 4°C (Beckman microfuge, Beckman Instruments, Palo Alto, CA) . The supernatant was removed and 0.1 ml of antiserum added. The mixture was incubated overnight at 4°C while being gently agitated.
  • the adsorbed material was centrifuged at 11,000 x g for 40 minutes and the supernatant was removed and added into a fresh bacteria pellet. The final supernatant was collected and stored at -20°C for Western blot analysis.
  • the culture grown bacteria was solubilized in a solution containing 0.062 M Tris, 0.069 M SDS and 1.09 M glycerol, pH 7.0.
  • the antigen preparation was then boiled for 10 minutes at 100°C to solubilize the bacteria. After the solubilized antigen had cooled, it was mixed with an equal volume of antibody and incubated overnight at 4°C. The mixture was centrifuged at 20,000 x g for 40 minutes to pellet the precipitated antibody-antigen complexes. The final supernatant was collected and stored at -20°C.
  • Antibody preparations used for the passive immunity study in mice were partially purified using ammonium sulfate. Serum samples were diluted 1:3 in sterile PBS. A solution of saturated ammonium sulfate was diluted to 90% of saturation and then added drop-wise to the diluted serum until a volume equivalent to the diluted serum was added, resulting in a 45% ammonium sulfate precipitation of the antibody. This solution was incubated on ice for 1 hour. The mixture was centrifuged at 10,000 x g for 40 minutes at 4°C to pellet the ammonium sulfate precipitate. The supernatant was discarded and the pellet was resuspended to the initial serum volume using sterile PBS. The ammonium sulfate precipitation was repeated to further purify the antibody. Following resuspension of the antibody, the solution was dialyzed against three changes of PBS using a 12,000 " MW cutoff membrane tubing.
  • Proteins from PmA were separated on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by electrotransfer and immunoblotting. Proteins from PmA isolates 8261 and 16926, both from in vivo and in vitro grown bacteria, were boiled for 10 minutes with 5X reducing buffer (Pierce, Rockford, IL) . The proteins were then separated on 10% SDS gels at a concentration of 16 ⁇ g per lane. After electrophoresis (20 n ⁇ constant amperage) , proteins were transferred on blotting membrane (Immobilon, Millipore, Bedford, MA) overnight at 4°C (30 volts, constant voltage) .
  • SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
  • the membrane was blocked with 10% non-fat dry milk in 10 mM Tris, 0.9% NaCl, pH 7.2 (Tris-saline) and strips were further incubated with appropriate dilutions of absorbed antiserum for 1 hour at room temperature. Subsequently, strips were rinsed 3 times with Tris-saline containing 0.1% Triton X-100 and further incubated 1 hour with alkaline phosphatase conjugated goat ⁇ -swine IgG (H+L) (Kirkegaard and Perry, Gaithersburg, MD) at a 1: 1000 dilution.
  • At least eleven protein bands with molecular weights of approximately 115 kD, 109 kD, 96 kD, 89 kD, 79 kD, 62 kD, 56 kD, 53 kD, 45 kD, 34 kD and 29 kD were identified from in vivo grown bacteria that were absent from or poorly expressed by culture grown PmA.
  • the molecular weights of proteins identified to be unique or up-regulated under in vivo growth conditions were estimated by Whole Band Analysis using the Biolmage Computer
  • All antibody preparations used in the passive immunity experiments were generated in swine against a primary infection with P. multocida isolate 8261, and in some cases were followed by a second infection with isolate 16926. Serum collected prior to the primary infection was used as a negative control for the passive immunity experiments. Convalescent serum from pig 104 was collected either at 30 days following the primary infection or at 7 days following the secondary exposure, and lung washings from pig 103 were collected 18 hours following the secondary infection. A secondary antibody response would be expected following re- exposure with the second strain. However, the secondary response should be limited to antigens that are common between the two Pasteurella multocida isolates.
  • the serum antibody preparations were adsorbed with detergent-solubilized bacteria and purified by ammonium sulfate precipitation as described in Example 4.
  • the partially purified antibody preparations were standardized by volume to represent a 1:10 dilution of the original serum sample. Lung washings were not adsorbed or purified.
  • mice were injected by the intraperitoneal route with 0.5 ml of the antibody preparations. Four- hours later the mice were infected with isolate 16926 at a rate of 100-200
  • mice Both the antisera collected after the primary challenge and the antisera collected after the secondary challenge passively protected mice against the 16926 challenge (9 of 10 and 8 of 10 mice survived at least ten days post infection, respectively) . These antisera were also adsorbed with detergent treated culture grown bacteria (8261) . Following adsorption, the antisera lost some of their protective capacity, but the death rate in these groups were still lower than in the control group that received preimmune serum.
  • mice given immune serum had better survival rates than that of the control mice that received preimmune serum.
  • the group given non-treated immune serum exhibited the highest survival rate (9 out of 10 mice survived the ten day challenge period) .
  • the antisera that had been detergent treated and purified provided intermediate protection. In these groups mice began dying between 6 and 10 days following challenge. No difference in survival time or mortality was seen between the mice that received detergent treated and purified antiserum versus the mice that received antiserum that had been adsorbed with detergent-solubilized culture grown bacteria and then purified.
  • Preimmune serum did not afford any passive protection in this model. All mice in this group died between 1 and 3 days post challenge. While the preimmune pig serum reacted with a few bacterial proteins in a Western blot analysis, the reactions were weak (1:10 dilution). This would be expected since the pigs used in these studies were not specific-pathogen free. Although they may have had some exposure to Pasteurella multocida or other pathogens with cross-reactive antigens, they were susceptible to Pa ⁇ teurella multocida at the time of primary infection, and did develop clinical disease following challenge.
  • Antibody recovered from the lung of an immune pig that had been originally infected with isolate 8261 and then exposed to a heterologous isolate of Pasteurella multocida was also tested for its ability to passively protect mice.
  • Antibody was recovered from the lung 18 hours after a secondary transthoracic exposure to Pasteurella multocida . This antibody recovered from the local site of exposure would have direct contact with invading bacteria.
  • Vascular leakage of specific antibody from the circulation into the extracellular environment of the lung represents an important immune mechanism that contributes to the protection seen in immune pigs following secondary exposure. Partial protection was seen in these mice, when compared to the control group. Five mice died within the first 1 to 3 days after challenge, but the remaining 5 mice lived an additional 4 to 5 days.
  • Bacteria P. multocida recovered from the pleural cavities of acutely infected pigs were isolated as described in Example 1. Isolate 8261 was also grown in culture as described in Example 1. Both preparations were inactivated with 0.3% formalin and adjusted to a concentration of 1 x 10 9 colony forming units (CFU)/ml. Each preparation was adjuvanted with a mineral oil emulsion containing 5% aluminum hydroxide gel. Five-fold and twenty- five-f ⁇ ld dilutions of the two vaccines were prepared by diluting the original vaccine in adjuvant. All vaccine preparations were administered by intraperitoneal injection into CF1 mice. Mice were vaccinated twice at a three week interval with a 0.1 ml dose.
  • CFU colony forming units
  • mice were challenged with 50 to 100 CFU of virulent Pasteurella multocida isolates 8261 or 16926 and observed for 15 days. As shown in Table 2 below, when the highest concentrations of vaccine were used, both preparations protected mice from both homologous and heterologous challenge. However, when less concentrated vaccines were used, only the vaccine produced from in vivo grown bacteria was able to protect the mice against virulent challenge. Eight of ten mice vaccinated with 1 x 10 7 CFU equivalents of in vivo antigens were protected against homologous challenge, and seven of ten mice were protected against heterologous challenge.
  • mice vaccinated with the least concentrated cultured bacterial antigens survived homologous challenge and only three of ten mice vaccinated with cultured bacterial antigens survived heterologous challenge. None of the ten non-vaccinated mice challenged with isolate 8261 survived, and only one of ten non- accinated mice challenged with isolate 19629 survived.
  • This test of active immunity in mice demonstrated that the addition of antigens that are up-regulated by in vivo growth produced a vaccine that was between 5 and 25 times as effective as a vaccine produced from bacteria grown in a standard, enriched media.
  • NA is representative of not applicable.
  • proteins from in vivo grown bacteria isolate 8261 were separated on 10% SDS gels. Western blots were performed simultaneously to identify the correct protein bands. Then, protein bands were excised from the gels, electroeluted and transferred to a PVDF membrane (ProBlott, Applied Biosystems) . Subsequently, protein bands (40-50 pmol each) were stained with 0.1 % Coomassie blue R-250 (Bio-Rad, Hercules, CA) . Individual protein bands were excised from the membrane for amino acid sequencing. Sequencing was performed on an Applied Biosystems Model A vapor phase protein sequencer at the Biotechnology Instrumentation Facility, University of California, Riverside, CA.
  • Balb C mice were immunized with in vivo grown P. multocida as described in Example 8, and then reimmunized with in vivo bacteria solubilized in SDS. Spleens from immunized mice were fused with SP2/0 myeloma cells to produce antibody-secreting hybridomas.
  • a hybridoma cell secreting antibody specific for the 109 kD protein was cloned -twice by limiting dilution and designated as Mab PMA 3-1. The resulting monoclonal antibody was specific for the 109 kD protein produced by in vivo grown bacteria and did not react with bacteria grown in complete media.
  • a second monoclonal antibody was selected based on the ability to bind the 29 kD protein from in vivo grown P. mul tocida .
  • Western blot analysis of in vivo grown and cultured bacteria demonstrated strong binding to the 29 kD protein of in vivo grown bacteria, and very little reactivity to culture grown bacteria.
  • This monoclonal antibody producing cell was cloned by limiting dilution and designated Mab PMA 3-21.
  • Example 12 Active Protection of Mice by Vaccine Produced from bacteria grown in minimal medium formulation P .
  • multocida isolate 8261 was cultured in a minimal medium formulation as described in Example 11.
  • Bacteria were also cultured in a standard, enriched media as described in Example 1 or harvested directly from the pleural cavities of infected swine as described in Example 1. All preparations were inactivated with 0.3% formalin with constant stirring for 24 hours at 37° C. The inactivated bacteria were diluted to a pre-inactivation cell count of 1 x 10 9 CFU/ml.
  • the bacterial suspensions were adjuvanted in a squalene emulsion containing Quil A and TDM.
  • mice female CF1, Charles River Laboratories
  • mice received two vaccinations three weeks apart and were challenged with either 380 LD S0 (50% lethal dose) of P. multocida 8261 or 209 LD 50 of isolate 16926 two weeks following the second vaccination.
  • mice immunized with vaccines prepared from in vivo grown bacteria or from bacteria cultured in either of the minimal media formulations had much better survival rates. These survival rates ranged from seven out of ten to complete protection (ten of ten mice) .
  • Example 13 Induction of "in vivo-like" antigens of Actinobacillus pleuropneumoniae
  • Bacteria were recovered from the pleural infusions of pigs that died or were euthanized following acute infection with Actinobacillus pleuropneumoniae . Fluids were collected into bottles containing glass beads to remove fibrin clots and then transferred to centrifuge bottles. Red blood cells and other cellular debris were removed by centrifugation at 900 x g for 15 minutes at 4°C. Bacteria were then recovered from the supernatant fluid by centrifugation at 14,000 x g for 15 minutes at 4°C. The bacterial pellet was resuspended in phosphate buffered saline (PBS) and washed three times by centrifugation and resuspension as above. The final bacterial pellet was resuspended in PBS to an optical density of approximately 3.0 and frozen at -70°C until analyzed.
  • PBS phosphate buffered saline
  • Actinobacillus pleuropneumoniae were also cultured in defined media #1, defined media #3 and complete HP media (see Table 3) . All media contained 10 mM nicotinamide adenine dinucleotide (NAD) . Cultured bacteria were centrifuged as above to concentrate the bacteria and remove media components. Bacterial pellets were resuspended in PBS to an optical density of approximately 3.0 and frozen at -70 "C until analyzed.
  • NAD nicotinamide adenine dinucleotide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Antigènes des espèces de bactéries Pasteurella, Actinobacillus et Haemophillus capables d'être régulés, dans le sens d'une augmentation, lors d'une infection dans un animal hôte et dans des formulations de milieu minimal assurant une protection contre les infections induites par ces espèces. Des compositions de vaccin contenant des antigènes des espèces de bactéries Pasteurella, Actinobacillus et Haemophilus sont également décrites, ainsi que des procédé d'immunisation d'animaux contre les infections par ces espèces.
PCT/IB1995/000185 1994-03-22 1995-03-20 Antigenes de pasteurellaceae et vaccins associes WO1995025742A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP7524520A JPH09505085A (ja) 1994-03-22 1995-03-20 パスツレラ科抗原および関連ワクチン
EP95910704A EP0751956A1 (fr) 1994-03-22 1995-03-20 ANTIGENES DE $i(PASTEURELLACEAE) ET VACCINS ASSOCIES
AU18600/95A AU1860095A (en) 1994-03-22 1995-03-20 (pasteurellaceae) antigens and related vaccines
MXPA/A/1996/004262A MXPA96004262A (en) 1994-03-22 1996-09-20 Antigens of pasteurellaceae and vaccines related

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21620294A 1994-03-22 1994-03-22
US08/216,202 1994-03-22

Publications (1)

Publication Number Publication Date
WO1995025742A1 true WO1995025742A1 (fr) 1995-09-28

Family

ID=22806147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1995/000185 WO1995025742A1 (fr) 1994-03-22 1995-03-20 Antigenes de pasteurellaceae et vaccins associes

Country Status (5)

Country Link
EP (1) EP0751956A1 (fr)
JP (1) JPH09505085A (fr)
AU (1) AU1860095A (fr)
CA (1) CA2186121A1 (fr)
WO (1) WO1995025742A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020934A1 (fr) * 1995-12-01 1997-06-12 Lo Reggie Y C Proteines de pasteurella haemolytica liant la transferine, et vaccins contenant ces proteines
KR970074928A (ko) * 1996-05-31 1997-12-10 에프, 지. 엠. 헤르만스; 이. 에이치. 리링크 파스퇴렐라 과의 약독화된 rtx 독소 생성 생 박테리아
US6610506B1 (en) 1995-12-01 2003-08-26 University Technologies International, Inc. Transferrin binding proteins of Pasteurella haemolytica and vaccines containing same
US8563004B2 (en) 2005-01-21 2013-10-22 Epitopix Llc Yersinia spp. polypeptides and methods of use
US11696945B2 (en) 2017-02-10 2023-07-11 Epitopix, Llc Proteins and immunizing compositions containing Pasteurella proteins and methods of use

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ546601A (en) 2003-09-19 2010-07-30 Epitopix Llc Compositions comprising at least six isolated metal regulated polypeptides obtainable from campylobacter spp

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0287206A1 (fr) * 1987-03-24 1988-10-19 Btg International Limited Vaccin contre pasteurella
US4957739A (en) * 1987-08-13 1990-09-18 Board Of Regents, The University Of Texas System Pharmaceutical compositions of a 105 kD P. Haemolytica derived antigen useful for treatment of Shipping Fever
WO1991015237A1 (fr) * 1990-04-05 1991-10-17 University Of Saskatchewan Compositions et traitements de la pneumonie chez les animaux
WO1992011023A1 (fr) * 1990-12-19 1992-07-09 Smithkline Beecham Corporation Immunopotentialisation de vaccins, notamment de vaccins contre la pleuropneumonie porcine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0287206A1 (fr) * 1987-03-24 1988-10-19 Btg International Limited Vaccin contre pasteurella
US4957739A (en) * 1987-08-13 1990-09-18 Board Of Regents, The University Of Texas System Pharmaceutical compositions of a 105 kD P. Haemolytica derived antigen useful for treatment of Shipping Fever
WO1991015237A1 (fr) * 1990-04-05 1991-10-17 University Of Saskatchewan Compositions et traitements de la pneumonie chez les animaux
WO1992011023A1 (fr) * 1990-12-19 1992-07-09 Smithkline Beecham Corporation Immunopotentialisation de vaccins, notamment de vaccins contre la pleuropneumonie porcine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHOI-KIM K. ET AL.: "Relationship between the iron regulated outer membrane proteins and the outer membrane proteins in vivo grown Pasteurella multocida", VETERINARY MICROBIOLOGY, vol. 28, no. 1, pages 75 - 92 *
HOMCHAMPA P. ET AL.: "Molecular analysis of aroA gene of Pasteurella Multocida and vaccine potential of a constructed aroA mutant", MOLECULAR MICROBIOLOGY, vol. 6, no. 23, pages 3585 - 3593 *
TAGAWA Y. ET AL.: "Purification and Partial Characterization of the Major Outer Membrane Protein of Haemophilus somnus", INFECTION AND IMMUNITY, vol. 61, no. 1, WASHINGTON US, pages 91 - 96 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020934A1 (fr) * 1995-12-01 1997-06-12 Lo Reggie Y C Proteines de pasteurella haemolytica liant la transferine, et vaccins contenant ces proteines
US6610506B1 (en) 1995-12-01 2003-08-26 University Technologies International, Inc. Transferrin binding proteins of Pasteurella haemolytica and vaccines containing same
KR970074928A (ko) * 1996-05-31 1997-12-10 에프, 지. 엠. 헤르만스; 이. 에이치. 리링크 파스퇴렐라 과의 약독화된 rtx 독소 생성 생 박테리아
US8563004B2 (en) 2005-01-21 2013-10-22 Epitopix Llc Yersinia spp. polypeptides and methods of use
US9085613B2 (en) 2005-01-21 2015-07-21 Epitopix, Llc Yersinia spp. polypeptides and methods of use
US9085612B2 (en) 2005-01-21 2015-07-21 Epitopix, Llc Yersinia spp. polypeptides and methods of use
US9109018B2 (en) 2005-01-21 2015-08-18 Epitopix, Llc Yersinia spp. polypeptides and methods of use
US9221899B2 (en) 2005-01-21 2015-12-29 Epitopix Llc Yersinia spp. polypeptides and methods of use
US9352029B2 (en) 2005-01-21 2016-05-31 Epitopix, Llc Yersinia spp. polypeptides and methods of use
US9801932B2 (en) 2005-01-21 2017-10-31 Epitopix, Llc Yersinia spp. polypeptides and methods of use
US11696945B2 (en) 2017-02-10 2023-07-11 Epitopix, Llc Proteins and immunizing compositions containing Pasteurella proteins and methods of use

Also Published As

Publication number Publication date
MX9604262A (es) 1997-12-31
JPH09505085A (ja) 1997-05-20
AU1860095A (en) 1995-10-09
EP0751956A1 (fr) 1997-01-08
CA2186121A1 (fr) 1995-09-28

Similar Documents

Publication Publication Date Title
US4888170A (en) Vaccines obtained from antigenic gene products of recombinant genes
US5294441A (en) Avirulent microbes and uses therefor: salmonella typhi
KR0139950B1 (ko) 무병원성 미생물 및 이의 용도
JP5566684B2 (ja) Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
CA1338705C (fr) Vaccins obtenus a partir de genes, antigenes de genes recombinants
EP0659086B1 (fr) Nouveaux vaccins bacteriens utilisant des souches vaccinales de bacteries pathogenes
US5855880A (en) Avirulent microbes and uses therefor
EP0500699B1 (fr) Vaccins de protection croisee contre la salmonella
JP2002541808A (ja) ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
MXPA00011075A (es) Mutantes atenuados de salmonella que constitutivamente expresan el antigeno vi..
Richards et al. Pathophysiological effects of Vibrio cholerae and enterotoxigenic Escherichia coli and their exotoxins on eucaryotic cells
EP0389347B1 (fr) Vaccins contre les bactéries septicémiques
JPH04504656A (ja) ボルデテラワクチン
AU666108B2 (en) CDT mutants of salmonella typhi
Roberts et al. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P. 69 and FHA
JP2999480B2 (ja) 百日咳感染及び毒性過程に対する保護抗原を得るための方法
JPH03502881A (ja) 淋菌ｐｉタンパク質およびワクチンの製造
SK91093A3 (en) Preparation and use of formalin-killed colonization-factor- -antigen (cfa)-expressing e. coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e. coli bacteria in humans
WO1995025742A1 (fr) Antigenes de pasteurellaceae et vaccins associes
EP0127153A2 (fr) Vaccins bivalents
JPH08785B2 (ja) トレポネマ・ハイオジセンテリアエのバクテリン
MXPA96004262A (en) Antigens of pasteurellaceae and vaccines related
EP0563288B1 (fr) Immunopotentialisation de vaccins, notamment de vaccins contre la pleuropneumonie porcine
Gorzynski et al. Production of common antigen by enteric bacteria grown in a synthetic culture medium
TW202214294A (zh) 具有ｈｙａＣ及ｎａｎＰ缺失之新穎多殺性巴斯德氏菌株及疫苗

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WR Later publication of a revised version of an international search report
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1996 702530

Country of ref document: US

Date of ref document: 19960905

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1996/004262

Country of ref document: MX

Ref document number: 2186121

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995910704

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995910704

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995910704

Country of ref document: EP